Drug
Apx005m
Apx005m: highest development phase Phase 1/2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| APX005M NCT03214250 | Phase 1/2 | Metastatic Pancreatic Adenocarcinoma |
Latest
No recent events.
Follow Apx005m on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.